Re: Farmas USA
Re: Farmas USA
Como que el patron de velas y pseudo Mornig Star de ayer venia avisando
------------------
TESARO up 7% premarket on reported Roche bid
Jun. 20, 2018 8:04 AM ET|About: Roche Holding Ltd ADR (RHHBY)|By: Douglas W. House, SA News Editor
TESARO (NASDAQ: TSRO) is up 7% premarket on modest volume in response to reported pending bid from Roche ( OTCQX:RHHBY). According to Intereconomy.com, the deal will be announced in the next few days.
The companies already have a relationship. In February, they announced their first clinical collaboration assessing the combination of ZEJULA (niraparib) and TECENTRIQ (atezolizumab) in bladder cancer. Another was announced several weeks ago.
Previously: TESARO teams up with Roche in combo therapy for bladder cancer (Feb. 26)
Previously: TESARO teams up with Roche to evaluate triplet therapy for ovarian cancer June 5
https://seekingalpha.com/news/3365148-tesaro-7-percent-premarket-reported-roche-bid
---
Tesaro: Consider Calls
https://seekingalpha.com/article/4182503-tesaro-consider-calls
Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
TSRO
Llevo con ella desde 77. Le perdí con el putt 45 a 6 meses. Al cerrarla, vendí 40 al viernes. Me llevé el 90% de la prima. Hizo 39,5 y 40,5 ese día.
Ya puestos vendí putt 30 septiembre y 25 diciembre.
Ha avisado tantas veces que al final viene el lobo hoy,,, me congratulo.
Aparte de AMD que estoy vendido con varias call era mi posición más comprometida.
Casi 46. Ambas putt en beneficios. Ya era hora.
Un saludo.
Si te sientas en la mesa y no descubres al "primo" es que lo eres tú.
Re: Farmas USA
TSRO
Breve artículo sobre el tema de DoctoRx...
Quick thoughts on Tesaro
https://seekingalpha.com/instablog/7256021-doctorx/5176624-quick-thoughts-tesaro
Summary
- Roche is reported to be close to a bid for Tesaro.
- Tesaro has a potential blockbuster in the making in Zejula.
- Tesaro, at only a $2.4 B market cap and a pipeline, could be an attractive bolt-on acquisition for many large biotechs, and could be a rewarding stock on its own.